Related references
Note: Only part of the references are listed.Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib
Qi Zhang et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?
Jessica J. Lin et al.
LANCET ONCOLOGY (2018)
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2018)
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation
Shan Su et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)
S.J. Antonia et al.
ANNALS OF ONCOLOGY (2017)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
CLINICAL CANCER RESEARCH (2017)
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy
Solene-Florence Kammerer-Jacquet et al.
TARGETED ONCOLOGY (2017)
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
Olivier Bylicki et al.
TARGETED ONCOLOGY (2017)
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?
Yi-Long Wu et al.
CANCER TREATMENT REVIEWS (2017)
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
K. Haratani et al.
ANNALS OF ONCOLOGY (2017)
MET/HGF pathway activation as a paradigm of resistance to targeted therapies
Brian Ko et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
What does PD-L1 positive or negative mean?
Antoni Ribas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer
Yaqi Li et al.
MOLECULAR CANCER (2016)
Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience
Ivana Sullivan et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)
EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
Kailong Lin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Akt/NF-κB signaling pathway for gastric cancer metastasis
Ning-Bo Hao et al.
CANCER LETTERS (2015)
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice
Miguel F. Sanmamed et al.
CANCER RESEARCH (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
MiR-20a Induces Cell Radioresistance by Activating the PTEN/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma
Yuqin Zhang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression
Murugabaskar Balan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations A Systematic Review and Meta-Analysis
Wu Feng Huang et al.
MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
NF-κB inhibition reveals a novel role for HGF during skeletal muscle repair
J. D. Proto et al.
CELL DEATH & DISEASE (2015)
Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma
Tongxin Liu et al.
MOLECULAR CANCER THERAPEUTICS (2015)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
Wei Wang et al.
CLINICAL CANCER RESEARCH (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Vaccination with immature dendritic cells combined with CD40 mAb induces protective immunity against B lymphoma in hu-SCID mice
Yan Ge et al.
BIOMEDICINE & PHARMACOTHERAPY (2010)
KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
Chen Mao et al.
LUNG CANCER (2010)
HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody
Wei Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
Seiji Yano et al.
CANCER RESEARCH (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Transcriptional activation of the Hepatocyte Growth Factor receptor (c-met) gene by its ligand (Hepatocyte Growth Factor) is mediated through AP-1
DW Seol et al.
ONCOGENE (2000)